79. Homozygous familial hypercholesterolemia Clinical trials / Disease details


Clinical trials : 142 Drugs : 114 - (DrugBank : 29) / Drug target genes : 9 - Drug target pathways : 18

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03933293
(ClinicalTrials.gov)
May 13, 201928/4/2019A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFHA Phase 2 Study to Evaluate the Safety and Efficacy of PCSK9 Inhibitor AK102 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)Homozygous Familial HypercholesterolemiaDrug: AK102;Drug: Statins;Drug: EzetimibeAkesoAD Pharmaceuticals Co., Ltd. (Guangzhou)Recruiting18 YearsN/AAll59Phase 2China
2NCT03510715
(ClinicalTrials.gov)
August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States
3NCT00704535
(ClinicalTrials.gov)
March 200623/6/2008Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino PatientsPrimary Hypercholesterolemia;Homozygous Familial HypercholesterolemiaDrug: EzetimibeOrganon and CoNULLCompleted18 YearsN/AAll4105Philippines
4NCT00092833
(ClinicalTrials.gov)
July 200223/9/2004Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous SitosterolemiaHypercholesterolemia, Familial;Lipid Metabolism, Inborn ErrorsDrug: Comparator: ezetimibeOrganon and CoNULLTerminated8 YearsN/AAll49Phase 3United States
5NCT03885921
(ClinicalTrials.gov)
October 25, 200020/3/2019Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Ezetimibe;Drug: Atorvastatin;Drug: SimvastatinOrganon and CoNULLCompleted12 YearsN/AAll44Phase 3NULL
6NCT03884452
(ClinicalTrials.gov)
May 3, 20006/3/2019Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial HypercholesterolemiaFamilial HypercholesterolemiaDrug: Atorvastatin;Drug: Simvastatin;Drug: Ezetimibe;Drug: Placebo for EzetimibeOrganon and CoNULLCompleted12 YearsN/AAll50Phase 3NULL